The investment will bring in cutting-edge downstream fermentation technology, strengthening the company’s contract manufacturing capabilities for drug substances
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
The segment delivered strong sales growth of 20% YoY
Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
Subscribe To Our Newsletter & Stay Updated
